praliciguat   Click here for help

GtoPdb Ligand ID: 9900

Synonyms: IW-1973 | IW1973
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Praliciguat (IW-1973) is a potent, orally available soluble guanylyl cyclase (sGC) stimulator [3]. sGC stimulators/activators have potential as heart failure therapeutics [1]. Praliciguat exhibits anti-hypertensive, reno-protective, anti-fibrotic effects and anti-inflammatory activities. Effects observed in renal fibrosis models suggests potential for the treatment of diabetic nephropathy.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 101.89
Molecular weight 534.11
XLogP 5.42
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Fc1cnc(nc1NCC(C(F)(F)F)(C(F)(F)F)O)c1nn(c(c1)c1nocc1)Cc1ccccc1F
Isomeric SMILES Fc1cnc(nc1NCC(C(F)(F)F)(C(F)(F)F)O)c1nn(c(c1)c1nocc1)Cc1ccccc1F
InChI InChI=1S/C21H14F8N6O2/c22-12-4-2-1-3-11(12)9-35-16(14-5-6-37-34-14)7-15(33-35)18-30-8-13(23)17(32-18)31-10-19(36,20(24,25)26)21(27,28)29/h1-8,36H,9-10H2,(H,30,31,32)
InChI Key CYSJNTQNMDWAJV-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
IW-1973 has reached Phase 2 clinical development. Clinical studies in patients with heart failure, hypertension and type 2 diabetes are underway (as of May 2018). Click here to link to the full list of IW-1973 trials registered at ClinicalTrials.gov.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03254485 A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Phase 2 Interventional Cyclerion Therapeutics The CAPACITY HFpEF study: praliciguat failed to significantly improve peak V̇o2 compared to placebo, in patients with HFpEF. 4